Pharmaceutical firm Caplin Point Laboratories declares Q4FY22 result: Total Annual Revenue at Rs. 1,308 Cr, up 21% YoY. PAT for the year up at Rs. 308 Cr, up 23% YoY. Cash Reserves at Rs. 694 Cr Top line of 2016 becomes Bottom line of 2022 Revenue for the year grew by 21% YoY to Rs. 1,308 Cr US Operating revenue grows 44% YoY to Rs. 122 Cr Gross margin for the year ended Mar’22 expanded by 53 bps to 56.1% PAT for the year is at Rs. 308 Cr up 22.7% YoY Cash and Cash Surplus at Rs. 694 Cr as of March 2022 – an increase of Rs 223 Cr over March 2021 balance. This increase is after a capex spend of Rs. 91 Cr during the year Free cash flow stood at Rs. 246 Cr as of Mar 22 Receivable days stand at 92 days as of Mar 22 Inventories are at Rs. 227 Cr (including in-transit inventory) Result PDF
Conference Call with Caplin Point Laboratories Management and Analysts on Q3FY22 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals and Biotechnology company Caplin Point Laboratories announced Q3FY22 results: Q3FY22 Revenue at Rs. 336 crore, up 19.8% YoY, as compared to Rs. 280 crore in Q3 FY21 Gross Margins improved to 55.9% in Q3FY22 from 54.8% in Q3FY21 PAT increased by 24.0% to Rs. 228 crore in 9MFY22 as against Rs.184 crore in 9MFY21 PAT for the quarter is at Rs. 79 crore up 20% as compared to Rs. 66 crore in Q3FY21 Cash flow From Operations at Rs 224 crore in 9MFY22 as against Rs 266 crore for the whole year FY21 Basic EPS grew by 25% to Rs. 29.18 in 9MFY22 against Rs. 23.25 in 9MFY21 (not Annualized) With continued focus on Cash Flow, Receivables sustained at 94 days despite growth in sales Inventory stood at Rs. 207 crore (including transit inventory of Rs.83 crore) in Dec 21 as against Rs. 237 crore in Sep 21. Considering the extended transit time and with a focus on need to keep Inventory closer to customers, the current level of inventory is likely to continue in Q4 as well. Geographical breakup of sales for 9MFY22: LATAM & ROW - 91%, US – 9% Result PDF